SPOTLIGHT -
VEW 2023: Phase 3 BRIO-I data for brimochol PF for presbyopia
Ben Bergo, CEO of Visus, shares data from the company's pivotal phase 3 BRIO-1 trial, as well as answers questions about Brimochol PF.